NDA 217759 · Pharming
Joenja
Leniolisib Phosphate · Oral
NovelPriority reviewOrphanCDER novel approval, Mar 24, 2023: To treat activated phosphoinositide 3-kinase delta syndrome
Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Mar 24, 2023
Approved uses
2
Original approval plus efficacy supplements
Registered trials
9
5 Phase 3, 1 recruiting
FAERS reports
937
177 serious, 7 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 30, 2026.
JOENJA is indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 4 years of age and older who weigh 27 kg or greater. ( 1 ) JOENJA is a kinase inhibitor indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 4 years of age and older who weigh 27 kg or greater.
Mechanism: Leniolisib inhibits PI3K-delta by blocking the active binding site of PI3K-delta. In cell-free isolated enzyme assays, leniolisib was selective for PI3K-delta over PI3K-alpha (28-fold), PI3K-beta (43-fold), and PI3K-gamma (257-fold), as well as the broader kinome. In cell-based assays, leniolisib reduced pAkt pathway activity and inhibited proliferation and activation of B and T cell subsets. Gain-of-function variants in the gene encoding the p110-delta catalytic subunit or loss of function variants in the gene encoding the p85-alpha regulatory subunit each cause hyperactivity of PI3K-delta....
Therapeutic areas: Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 11, 2026 Supplement 6 · Efficacy · priority review OrphanLetterLabel
- Mar 24, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
3 products under this application
- JOENJA · LENIOLISIB PHOSPHATE EQ 40MG BASE · TABLET, ORAL · Prescription
- JOENJA · LENIOLISIB PHOSPHATE EQ 50MG BASE · TABLET, ORAL · Prescription
- JOENJA · LENIOLISIB PHOSPHATE EQ 70MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Leniolisib" as an intervention, any sponsor and status, largest first.
- Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLIPivotal-lookingTerminated
Pharming Technologies B.V.Industry
NCT02859727 · 37 participants · Start Sep 8, 2016 · Primary completion Jan 30, 2025
Drug: CDZ173 · For: Activated PI3Kdelta Syndrome (APDS); PASLI Disease
Sites: Bethesda, Maryland; Minsk, Belarus; Prague, Czechia · 8 sites in all
- Study of Efficacy of CDZ173 in Patients With APDS/PASLIPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02435173 · 37 participants · Start Aug 24, 2015 · Primary completion Aug 16, 2021
Drug: CDZ173 · For: Common Variable Immunodeficiency (CVID), APDS / PASLI
Sites: Bethesda, Maryland; Minsk, Belarus; Prague, Czechia · 10 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT02775916 · 30 participants · Start Jun 1, 2016 · Primary completion May 17, 2017
Drug: CDZ173; Placebo · For: Primary Sjögren's Syndrome
Sites: Berlin, Germany; Debrecen, Hungary
Pharming Technologies B.V.Industry
NCT06897358 · 27 participants · Start Feb 12, 2025 · Primary completion Aug 12, 2026
Drug: Leniolisib · For: Common Variable Immunodeficiency (CVID)
Sites: Aurora, Colorado; Bethesda, Maryland; Burlington, Massachusetts · 7 sites in all
- Pediatric Patients Aged 1 to 6 Years With APDSPivotal-lookingActive, not recruiting
Pharming Technologies B.V.Industry
NCT05693129 · 16 participants · Start Aug 30, 2023 · Primary completion Jul 9, 2028
Drug: Leniolisib · For: APDS
Sites: Los Angeles, California; Bethesda, Maryland; Shaker Heights, Ohio · 9 sites in all
- Pediatric Patients Aged 4 to 11 Years With APDSPivotal-lookingActive, not recruiting
Pharming Technologies B.V.Industry
NCT05438407 · 15 participants (planned) · Start Feb 1, 2023 · Primary completion Nov 30, 2026
Drug: Leniolisib · For: APDS
Sites: Los Angeles, California; Standford, California; Atlanta, Georgia · 7 sites in all
Pharming Technologies B.V.Industry
NCT06549114 · 13 participants · Start Oct 21, 2024 · Primary completion Jun 23, 2026
Drug: Leniolisib · For: Primary Immunodeficiency Disorders (PIDs)
Sites: Bethesda, Maryland
- Long-term Safety and Efficacy of Leniolisib in PIDs With Immune DysregulationActive, not recruiting
Pharming Technologies B.V.Industry
NCT06990529 · 12 participants (planned) · Start Apr 29, 2025 · Primary completion Aug 12, 2029
Drug: Leniolisib · For: PIDs Linked to PI3K
Sites: Bethesda, Maryland; Burlington, Massachusetts; New York, New York · 5 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- infection153
- product dose omission issue133
- off label use67
- sinusitis63
- headache47
- nasopharyngitis44
- fatigue32
- ear infection29
- pneumonia29
- diarrhoea27
- nausea24
- alopecia23
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2022 | 1 |
| 2023 | 128 |
| 2024 | 222 |
| 2025 | 290 |
| 2026 | 295 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Joenja (Leniolisib Phosphate)
2024 spending
$3.9M
Beneficiaries
n/a
81 claims
Per beneficiary
n/a
$803.08 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $2,256,027 |
| 2024 | $3,902,966 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome.
Rao VK, Webster S, edivá A, et al. · Blood 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Clinical, Immunological, and Genetic Features in Patients with Activated PI3Kδ Syndrome (APDS): a Systematic Review.
Jamee M, Moniri S, Zaki-Dizaji M, et al. · Clin Rev Allergy Immunol 2020 · Meta-Analysis, Systematic Review
- A randomised, placebo-controlled, phase III trial of leniolisib in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): Adolescent and adult subgroup analysis.
Rao VK, edivá A, Dalm VASH, et al. · Clin Immunol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Evaluating the impact of leniolisib treatment on symptoms and health-related quality of life in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome.
Rao VK, Morgan A, Torgerson TR, et al. · Front Immunol 2026 · Randomized Controlled Trial
- CYP3A but not P-gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta-specific phosphoinositide-3 kinase inhibitor leniolisib.
De Buck S, Kucher K, Hara H, et al. · Biopharm Drug Dispos 2018 · Clinical Trial
- 19F-NMR-based determination of the absorption, metabolism and excretion of the oral phosphatidylinositol-3-kinase (PI3K) delta inhibitor leniolisib (CDZ173) in healthy volunteers.
Pearson D, Garnier M, Luneau A, et al. · Xenobiotica 2019 · Randomized Controlled Trial
Sponsor: Pharming
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.